Trademark Search in Canada

ZURELIDY

View On IC.GC.CA

FORMALIZED

on 28 Feb 2024

Last Applicant/ Owned by

Lantheus Medical Imaging, Inc.

201 Burlington Road, South BuildingBedford MA 01730

Serial Number

2312958 filed on 10^th Jan 2024

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

K1P1C3

ZURELIDY

Trademark usage description

radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disor Read More

Classification Information

Class [005]
Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer.

Classification kind code

Mark Details

Serial Number

2312958

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 135 on 9^th Jan 2025	Amendment to Application
Submitted for opposition 256 on 31^st Dec 2024	Notification of Possible Opposition Sent
Submitted for opposition 48 on 4^th Apr 2024	Agent Changed
Submitted for opposition 257 on 29^th Feb 2024	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 28^th Feb 2024	Formalized
Submitted for opposition 1 on 28^th Feb 2024	Created
Submitted for opposition 228 on 10^th Jan 2024	International Registration
Submitted for opposition 30 on 10^th Jan 2024	Filed

ZURELIDY

Classification Information

Class [005]Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer.